Skip to main content

Table 1 Patient backgrounds

From: Efficacy of combined use of Suvorexant and Ramelteon in preventing postoperative delirium: a retrospective comparative study

Ā 

Combined-admin. group

(nā€‰=ā€‰50)

No-hypnotic group (nā€‰=ā€‰60)

P

Age

Ā Ā Ā 

ā€ƒ74 or younger

24 (48.0%)

42 (70.0%)

0.031a

ā€ƒ75 or older

26 (52.0%)

18 (30.0%)

Ā 

Gender

Ā Ā Ā 

ā€ƒMale

20 (40.0%)

38 (63.3%)

0.021a

ā€ƒFemale

30 (60.0%)

22 (36.7%)

Ā 

Operative procedure

Ā Ā Ā 

ā€ƒHepatectomy

20 (40.0%)

27 (45.0%)

0.373b

ā€ƒPancreatectomy

19 (38.0%)

25 (41.7%)

Ā 

ā€ƒOthers

11 (22.0%)

8 (13.3%)

Ā 

Performance status

Ā Ā Ā 

ā€ƒ0

32 (64.0%)

36 (60.0%)

0.698a

ā€ƒ1ā‰¤

18 (36.0%)

24 (40.0%)

Ā 

History of alcohol intake

31 (62.0%)

41 (68.3%)

0.548a

Previous disease

Ā Ā Ā 

ā€ƒHypertension

24 (48.0%)

32 (53.3%)

0.702a

ā€ƒMental disorder

8 (16.0%)

1 (1.7%)

0.011a

Adjuvant remedy

Ā Ā Ā 

ā€ƒOpioid

0 (0.0%)

2 (3.3%)

0.500a

ā€ƒAntidopaminergic drug

0 (0.0%)

1 (1.7%)

1.000a

ā€ƒH2 receptor antagonist

25 (50%)

29 (48.3%)

1.000a

ā€ƒSteroid

0 (0.0%)

3 (5.0%)

0.249a

  1. a. Fisherā€™s exact test
  2. b. Cochrane-Armitage trend test